Arcus Biosciences (RCUS) Stock Forecast & Price Target

Arcus Biosciences is a Hayward, California based biopharmaceutical company focused on developing novel immunotherapies for the treatment of cancer, with a product pipeline including Domvanalimab, Quemliclustat, and Casdatifan. While risks to the achievement of their price target and rating include clinical and regulatory failure and commercial competition, early data has shown promising results, with monotherapy cohorts demonstrating a mPFS of 12.2 months and cORR of 35% and combo data showing a cORR of 46% with a low primary progressive disease rate of 5%. Additionally, a recent FDA decision has set a PDUFA date of 2026 for their combo treatment, allowing for further enrollment in the ongoing PEAK-1 trial.

Arcus Biosciences is leveraging differentiated TKI-free regimens for the treatment of frontline ccRCC, with potentially more attractive PPD rates than the current standard of care. However, the market may be impacted by Merck's ongoing LITESPARK-012 study in combination with belzutifan and potential competition from cas plus cabo in the 2L after 1L treatment with the triplet regimen. Despite the potential for market share in the short-term, long-term demand for TKI-free regimens is expected to increase.